Ivermax

Quick links to important sections

Ivermax

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ivermax

Ivermax is the commercial name for a medication containing the active ingredient Ivermectin, a substance widely recognized for its antiparasitic chemotherapy applications. The medication's general purpose is to aid the body in the rapid elimination of internal and external parasitic invaders.

Property Description
Active ingredient Ivermectin
Form Oral tablet, topical cream/lotion
Pharmacological class Anthelmintic, Macrocyclic Lactone
Common use Antiparasitic chemotherapy
Origin Semisynthetic derivative

What Type of Medicine is Ivermax?

Ivermax is primarily classified as an anthelmintic and antiparasitic agent, belonging to the macrocyclic lactone class of drugs. This classification characterizes its active compound, Ivermectin, through its selective mode of action.

The active ingredient is an endectocide, which means it is effective against both endoparasites (internal worms, such as certain Nematodes) and ectoparasites (external invaders, like mites). This broad-spectrum capability reflects its clinical versatility in interrupting parasitic life cycles in multiple body compartments.


Is Ivermax a Natural Derivative? (Composition and Origin)

The core substance, Ivermectin, is accurately described as a semisynthetic derivative, meaning it is chemically altered from a potent naturally occurring compound. The original compound, known as Avermectin, is isolated from the fermentation products of the soil bacterium Streptomyces avermitilis.

Ivermax is a single-agent product supplied in different pharmaceutical preparations, most commonly as an oral tablet or a topical cream or lotion, which determine the route of administration. The specific formulation is designed for targeted delivery; for example, its topical form is highly concentrated for localized treatment of dermatological issues.


What is the General Purpose of Ivermax?

The general therapeutic purpose of Ivermax is to provide highly targeted intervention against parasitic organisms in the body. It works by interfering with the nerve and muscle functions of the worms, paralyzing and killing them. The medicine is designed to stop the invaders from moving and feeding, leading to a quick reduction in the overall parasitic load and supporting the body's elimination of the organisms.

Regulatory References

  1. paralyzing and killing
  2. elimination
  3. oral tablet
  4. topical cream
  5. parasitic load

What side effects are possible with Ivermax?

The officially documented safety profile for Ivermax (Ivermectin) is established through clinical trials and post-marketing surveillance for its approved antiparasitic uses. Adverse reactions are formally classified by frequency and grouped according to the body system affected, consistent with regulatory standards (e.g., FDA and EMA).


Officially Classified Adverse Reactions

Common reactions typically involve the skin, gastrointestinal, and nervous systems. These frequently reported events include pruritus (itching), rash, headache, dizziness, nausea, vomiting, diarrhea, fever, and arthralgia (joint pain). These effects are often transient.

Uncommon and Rare events, as noted in regulatory documents, include transient tachycardia (fast heart rate), somnolence, and vertigo.


Serious Adverse Reactions and Safety Constraints

Regulatory documents identify certain reactions as potentially serious. In the treatment of onchocerciasis, a Mazzotti-type reaction—an inflammatory response linked to the death of microfilariae—is a time-related pattern that may occur shortly after therapy begins. Rare but severe skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have also been reported.

Official labeling defines specific constraints: the medication is contraindicated in individuals with a known hypersensitivity to Ivermectin. Caution is also advised for patients with hepatic impairment and for conditions that could compromise the blood-brain barrier, due to the potential for increased neurological adverse events. The safety profile is not established for children weighing less than 15 kg.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose with Ivermax (Ivermectin) is officially documented to involve a range of clinical and physiological effects, focusing primarily on the central nervous system (CNS) and cardiovascular system. Documented manifestations include gastrointestinal effects such as nausea, vomiting, and diarrhea. More critical signs observed are confusion, loss of coordination (ataxia), tremors, and visual disturbances. Severe or life-threatening outcomes reported in regulatory documents include seizures, coma, respiratory failure, and death. Cardiovascular effects such as hypotension (low blood pressure) and tachycardia (fast heart rate) have also been officially documented.

Management and Required Emergency Action

Due to the drug's established toxicity profile, immediate medical attention must be sought if any suspected overdose symptoms are experienced. In cases involving collapse, seizures, difficulty breathing, or inability to be awakened, emergency medical services must be contacted immediately. Regulator-approved management confirms that no specific antidote is known for Ivermectin overdose. Treatment is therefore symptomatic and supportive, focusing on maintaining vital signs. Procedures like gastric decontamination, including activated charcoal or gastric lavage, may be considered by medical professionals following large ingestions. It is noted that Ivermectin may potentiate CNS depression if taken in overdose alongside other CNS depressants, such as benzodiazepines.

Therapeutic Uses of Ivermax

Quick Facts

  • Oral Uses: Management of intestinal strongyloidiasis (threadworm) and onchocerciasis (river blindness) due to parasitic worm infections.
  • Topical Uses: Treatment of head lice infestation and inflammatory lesions associated with rosacea.

Ivermax (Ivermectin) is an agent that addresses several conditions caused by parasites. The medication is utilized for targeted use against specific parasitic infections in humans.

Core Therapeutic Domains

In its oral formulation, Ivermax is administered to address two primary parasitic worm infections: Intestinal Strongyloidiasis and Onchocerciasis (commonly known as river blindness). Management of these conditions involves helping to clear the body of the parasites responsible for the infection.

Additionally, topical formulations of Ivermax are utilized to manage certain skin and external parasite conditions. These applications include providing relief for head lice infestations and assisting in the resolution of inflammatory lesions associated with rosacea.

It is important to note that the use of any medication should align with clinical guidelines.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Ivermax — Official Regulatory Information

The eligibility for Ivermax (Ivermectin) is strictly governed by regulatory documentation, defining specific groups who are either excluded or require conditional use.

Category Official Regulatory Status
Contraindicated Populations Hypersensitivity to Ivermectin or any excipient.
Minimum Weight Exclusion Children weighing less than 15 kg (oral use); safety and efficacy not established.
Conditional Use (Comorbidity) Patients with high Loa loa microfilarial load; eligibility requires pretreatment assessment.
Conditional Use (Organ Function) Severe Hepatic Impairment (use with caution due to liver metabolism).
Pregnancy Eligibility Status Not Recommended (Category C); use only if potential benefit justifies risk.
Lactation Eligibility Status Not Recommended; decision required to discontinue nursing or the medicine.
Older Adults Use with caution due to potential decreased organ function.

Eligibility classifications (high-level)

Classification Basis
Severity Classification Contraindicated, Not Established, Not Recommended, Use with Caution.
Context Constraints Weight-based (oral: 15 kg), Physiological state (Pregnancy/Lactation), Disease-specific (Loa loa).

Connection to the overall eligibility profile:

Regulatory documents define the scope of who can and cannot use the medicine by establishing an absolute contraindication (hypersensitivity) and several categories of restricted eligibility. This profile is primarily structured around minimum body weight for pediatric patients and cautionary statements related to organ function and physiological states like pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official interaction profile for Ivermax, based on regulatory documentation, defines specific constraints across medicinal products, substance classes, and patient populations.

Category Official Regulatory Statement
Medicinal product categories Potent CYP3A4 inhibitors are noted due to their effect on Ivermectin clearance.
Specific interacting medicines Warfarin (due to rare post-marketing reports of increased INR); Diethylcarbamazine citrate (DEC).
Mechanistic basis Pharmacokinetic: Metabolism primarily via the CYP3A4 enzyme. Pharmacodynamic: Potential additive effect on coagulation with warfarin.
Timing constraints Administration following a standard high-fat meal results in an approximate 2.5-fold increase in bioavailability.
Population-specific note Patients co-infected with Loa loa are noted to have an increased risk of serious CNS adverse experiences.
Interaction restrictions Co-treatment with Diethylcarbamazine citrate (DEC) is not recommended in certain mass chemotherapy settings.

Official Interaction Statements

  • Co-administration with potent CYP3A4 inhibitors may be associated with a significant increase in Ivermectin plasma exposure.
  • Post-marketing reports have documented rare cases of increased International Normalized Ratio (INR) when combined with warfarin.
  • The regulatory label notes that a standard high-fat meal can increase Ivermectin's bioavailability by approximately 2.5-fold.
  • Alcohol (ethanol) co-ingestion is noted as potentially increasing the risk of side effects such as sleepiness and dizziness.
  • The risk of serious Central Nervous System (CNS) adverse experiences is increased in patients who are co-infected with the parasite Loa loa.

The official regulatory profile is structured around both pharmacokinetic clearance and pharmacodynamic risk. Labeling documents note the effect of CYP3A4 inhibitors on drug exposure and formally identify specific pharmacodynamic concerns with drugs like warfarin. Furthermore, the profile includes restrictions based on specific clinical contexts, such as co-infection with Loa loa and the administration timing relative to food intake.

Mechanism of Action

Mechanism of Action: How Ivermax Works

Ivermax (Ivermectin) exerts its effects by selectively targeting Glutamate-gated Chloride Ion Channels ( GluCls), which are unique to invertebrate nerve and muscle cells. It acts as an agonist, binding with high affinity to the channel's transmembrane domain. This interaction induces a conformational change, forcing the GluCl channel to open and remain open, initiating a massive, sustained influx of chloride ions ( Cl^-) into the cell.

This continuous Cl^- influx results in the irreversible hyperpolarization of the parasite's nerve and muscle cell membranes, fundamentally disrupting their ability to transmit signals or contract. This molecular cascade leads directly to complete and sustained paralysis of the parasite's somatic and pharyngeal musculature, resulting in functional incapacitation.

Activity is confined to invertebrates due to two factors in mammals: the absence of the high-affinity GluCl channel and the low permeability across the blood-brain barrier ( BBB). This extrinsic mechanism, primarily mediated by the P-glycoprotein pump, limits the modulation of host central nervous system signaling pathways.

Dosage and Administration Information

How Ivermax is Used: Administration Guidelines

Ivermax (Ivermectin) is administered through distinct routes, primarily as an oral tablet for systemic antiparasitic action or as a topical formulation for external use. The guidelines for administration are specific to each form, with the dosing and schedule characterized by the treatment type.

Oral Tablet Administration

The oral tablet is dosed based on the patient's body weight. Common regimens utilize either 200 mcg per kilogram (kg) or 150 mcg/kg for a single administration, depending on the infection targeted. This weight-based calculation is used to determine the appropriate dose.

Oral tablets are swallowed with water on an empty stomach. No food is consumed for two hours before or two hours after the dose to support proper absorption. For pediatric patients, oral use is limited to those weighing 15 kg or more, and tablets for children under 6 years of age can be crushed before swallowing. While treatment for certain conditions is typically a single dose, others may involve retreatment every 3 to 12 months as part of an intermittent schedule.

Topical Administration

Topical formulations (cream and lotion) are for external use only and are not for oral or ophthalmic use. The cream, used for dermatological conditions, is applied as a pea-size amount to each affected area of the face once daily. The lotion, used for head lice, is applied as a single coat to dry hair and scalp, left in place for 10 minutes, and then rinsed off with water.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ivermax

This section describes the research that has been conducted for the approved uses of Ivermax. It provides an overview of the types of studies available, what outcomes were monitored by researchers, and areas where evidence is still emerging or limited. This information describes group patterns observed in studies and does not determine whether an individual will respond similarly.

Evidence for Use in Intestinal Strongyloidiasis (Threadworm)

Research for threadworm infection has involved Randomized Controlled Trials (RCTs) and systematic reviews. Researchers measured parasitological cure rate, which is the absence of the S. stercoralis parasite, confirmed by laboratory tests. The studies report measurements of parasitological clearance in the groups observed.

What remains uncertain is the need for more research to fully establish the long-term, sustained absence of the parasite from host tissues. Data are still emerging for complex presentations of the condition, such as cases of severe hyperinfection.

Evidence for Use in Onchocerciasis (River Blindness)

Evidence comes from RCTs and extensive observational cohorts from large-scale, long-running community treatment programs. The primary outcomes monitored included measurements related to microfilariae count (immature worms) from the skin, as well as the long-term changes in symptoms related to the eyes and vision. Research highlights changes measured during the study period, consistently describing a noticeable change in the measured microfilarial load.

Evidence is limited regarding the compound's effect against the adult worm (macrofilaricidal activity). Research is ongoing to monitor for any potential changes in parasite response to the compound.

Research in Specific Populations and Subgroups

Research has explored various age groups for the parasitic infections. The outcomes of these studies reflect the populations examined and should not be broadly generalized. Data for certain groups, such as pregnant individuals or those with significant underlying conditions, remain insufficient. Subgroup findings are uncertain when trying to apply the research outside the specific parameters of the clinical trials.

Gaps in Evidence and Areas of Ongoing Research

Scientific analysis highlights several areas where more research is needed or where certainty remains low. Follow-up durations were limited for the topical uses (Rosacea and Head Lice). Comparative evidence is lacking in some areas, and research is ongoing to continually monitor the development of potential resistance in the parasites. These limitations demonstrate that evidence highlights what is known — and what is still uncertain — about the use of Ivermax.

Key Studies & References

  1. Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (NICE Guidance)

Frequently Asked Questions (FAQ)

Common questions about Ivermax (FAQ)


Q: How quickly should I expect Ivermax to start working?

A: Pharmacodynamic data indicate that the active ingredient, Ivermectin, begins its intended action by paralyzing the target parasites upon being absorbed. The time it takes to see the full clinical effect can vary depending on the specific condition being treated. For the management of chronic infections like Onchocerciasis, the peak therapeutic effect may be noted several months following administration.


Q: Does Ivermax cause fatigue or tiredness?

A: Official product information includes reports of certain nervous system effects. Side effects such as fatigue and sleepiness (somnolence) have been reported as possible adverse reactions. These effects are generally described as temporary.


Q: Can Ivermax affect my liver or kidney function?

A: Regulatory documents advise caution regarding liver function. Because the active ingredient is extensively metabolized by the liver, its use requires careful consideration for patients with existing hepatic disease. There are no specific concerns noted in official documentation regarding adverse effects on kidney function.


Q: Can I take Ivermax if I am taking blood thinners?

A: Co-administration with blood-thinning medications is described in the regulatory label. Post-marketing reports have rarely documented an increased International Normalized Ratio ( INR) when Ivermax is combined with warfarin. All medications being taken, including blood thinners, are factors for a health provider to consider.


Q: What is a contraindication, and are there any for Ivermax?

A: A contraindication is an official statement that a specific medical reason exists to withhold a treatment because the potential risk is considered unacceptable. For Ivermax, the only absolute contraindication is a known hypersensitivity (a severe allergic reaction) to Ivermectin or any of the product’s non-active ingredients.


Q: Are there different strengths of Ivermax, and what does that mean?

A: Yes, Ivermax oral tablets are commonly available in different strengths, with 3 mg being a typical size mentioned in regulatory documents. The available strengths are relevant for calculating the appropriate weight-based amount for administration, as defined for the specific infection.


Q: Will I feel anything different right after taking Ivermax?

A: Many patients feel nothing unusual, but some may experience common reactions such as dizziness, nausea, or a headache soon after administration. For the treatment of certain parasitic infections, a temporary inflammatory reaction known as a Mazzotti-type reaction may occur, which is related to the death of the target parasites.


Q: What is the expected outcome if Ivermax works as intended?

A: The intended outcome of Ivermax is the paralysis and death of the targeted parasites, which leads to the reduction of the overall parasitic load in the body. The goal of administration, confirmed by follow-up tests showing the absence of the parasite, is the achievement of a parasitological cure.


Q: What are the long-term effects described in official documents?

A: Official regulatory documents typically focus on acute and subacute side effects, as well as rare severe reactions identified through post-marketing surveillance. Data on effects extending years beyond the standard follow-up for the treated parasitic infections are limited or not fully summarized in the official labeling.


Q: Does Ivermax affect a person's ability to drive or operate machinery?

A: Regulatory documents advise caution regarding tasks that require alertness. Because the drug can cause side effects such as dizziness and sleepiness (somnolence), regulatory documents advise that these effects may affect the ability to drive or operate machinery.


Q: Can Ivermax be crushed or dissolved in water?

A: The official administration guidelines address this for children. Specifically, the tablet form is permitted to be crushed for use in young pediatric patients who are unable to swallow the pill whole. This instruction is not generally provided for adult patients.


Q: Are there any common over-the-counter drugs that interact with Ivermax?

A: The official label advises care when co-administering any medications that are known to inhibit the CYP3A4 enzyme, which is involved in breaking down Ivermax. A health provider should be aware of all over-the-counter ( OTC) medications taken, including common pain relievers, to assess potential interactions.


Q: What if I have a pre-existing condition, like asthma or diabetes?

A: General caution is advised for patients with underlying medical conditions, especially those that could compromise the blood-brain barrier or involve the liver. While diabetes is not specifically listed as a precaution, post-marketing reports have sometimes noted a temporary worsening of asthma in some patients.


Q: What happens if I miss a scheduled amount of Ivermax?

A: Ivermax is often prescribed as a single, one-time treatment. If a scheduled dose or retreatment is missed, this may require contacting a prescribing doctor for review. This is important because the need for retreatment is often decided based on specific follow-up lab tests.


Q: How long does Ivermax stay in my system?

A: Pharmacokinetic data from official sources indicate that the plasma elimination half-life of the active ingredient is approximately 18 hours after oral administration. This means it takes about that long for half of the drug to be eliminated from the bloodstream.


Q: Can I get Ivermax without a prescription?

A: The requirement for a prescription varies depending on the formulation and country. Most oral forms of the medicine require a prescription. However, some topical formulations, such as the lotion used for treating head lice, may be available for purchase over-the-counter ( OTC).


Q: What is the difference between brand-name Ivermax and generic?

A: Regulatory bodies like the FDA consider generic versions to be chemically identical to the brand-name medication. The generic contains the exact same active ingredient (Ivermectin) and is considered to be as safe and effective as the brand-name version.


Q: Is Ivermax known to interact with herbal supplements?

A: There are no specific reports in official documentation of the active ingredient interacting with common herbal supplements or vitamins. However, supplements, vitamins, and herbal products are factors generally discussed with a doctor.


Q: What should I do if I feel worse after starting Ivermax?

A: Official sources state that emergency services or a doctor should be contacted immediately if signs of a serious reaction are experienced. This includes symptoms such as seizures, confusion, difficulty breathing, or severe sleepiness.


Q: How does Ivermax affect my immune system?

A: The mechanism of Ivermax is highly specific to the parasite's nerve cells and does not directly target the host's immune system. However, in certain parasitic treatments, the rapid death of microfilariae can provoke an inflammatory response (the Mazzotti-type reaction) in the patient.


Q: Where can I find official research papers on Ivermax?

A: Official prescribing information and regulatory labels often contain citations and references for the clinical trials and research that were conducted. These references support the drug’s approved uses and can direct users toward the underlying data.


Q: Is Ivermax described as an anti-inflammatory drug?

A: No, Ivermax is officially classified by health bodies as an Anthelmintic and Macrocyclic Lactone. Its primary purpose is antiparasitic chemotherapy, not general anti-inflammatory treatment.


Q: Can I take pain relievers while using Ivermax?

A: Official documentation does not list a specific interaction with common pain relievers, such as acetaminophen or ibuprofen. However, a healthcare provider review is required before co-administering any medications, including over-the-counter pain relievers.


Q: What are the signs of taking too much Ivermax?

A: Official documentation describes a profile of potential overdose symptoms. These may include rash, headache, dizziness, nausea, vomiting, diarrhea, seizures, confusion, and loss of consciousness.


Q: What does 'not for human consumption' mean when I see it related to this medicine?

A: The FDA has issued public warnings about the dangers of using non-human, or veterinary, formulations of the active ingredient. These products are formulated and regulated differently and should not be used by humans.


Q: How is the use of Ivermax monitored by health providers?

A: Monitoring often involves specific follow-up procedures. After treatment, health providers may use laboratory tests such as microfilariae counts or stool examinations to confirm that the parasite is no longer present and that a parasitological cure has been achieved.


Q: Is there a maximum time I can use Ivermax?

A: For chronic conditions like Onchocerciasis, retreatment is necessary and is scheduled on an intermittent basis (e.g., every 3 to 12 months) to control the parasite. An absolute maximum lifetime duration of therapy is not typically defined in official documents.


Q: Does Ivermax interact with grapefruit or grapefruit juice?

A: The active ingredient is metabolized by the CYP3A4 enzyme system in the body. While a specific grapefruit interaction is not always listed, grapefruit is a known CYP3A4 inhibitor and, like other inhibitors, could potentially affect the body's exposure to the medication.


Q: Are there any lab tests I need to have done while using Ivermax?

A: Yes, to monitor treatment success, patients are often followed up with laboratory tests. These may include microfilariae counts or stool examinations to ensure the elimination of the parasite after the treatment regimen is complete.


Q: Why is Ivermax sometimes mentioned alongside a specific virus?

A: During recent public health events, the FDA issued specific statements regarding the use of Ivermax for the treatment or prevention of COVID-19. The agency clarified that the drug is not approved for this viral purpose.


Q: What are the signs that Ivermax may not be working?

A: The primary sign that the drug may not have worked is the continued presence of the parasite in the body. This is determined and confirmed by a healthcare provider through follow-up lab testing, such as analyzing stool samples or microfilariae counts after the treatment has been given.


Q: Is there an official patient information leaflet for Ivermax?

A: Yes, official regulatory documents, such as the Structured Product Label ( SPL) or Summary of Product Characteristics ( SmPC), serve as the basis for the patient information leaflet that is required to accompany the medication.

How should Ivermax be stored and disposed of?

The storage and disposal of Ivermax (Ivermectin) are strictly governed by regulatory labeling to maintain product stability and protect the environment.

Storage Conditions

Ivermax must be stored at controlled room temperature, specifically 20°C to 25°C (68°F to 77°F), with permitted excursions between 15 C and 30 C. The product must be kept from freezing, protected from light and excess moisture, and stored in its original container, tightly closed.

Safety and Disposal

All Ivermax formulations must be stored strictly out of the sight and reach of children.

Due to the medication's toxicity to aquatic life, official regulatory documents state that unused or expired Ivermax must not be disposed of via wastewater or household trash. Disposal must be performed in accordance with local requirements, often utilizing a medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ivermax found in:

A-Z Index: